Exceedingly Rare Genetic Variants in Inflammasome Pathways Linked to Increased Multiple Sclerosis Risk

The study titled "Multiple Sclerosis Patients Carry an Increased Burden of Exceedingly Rare Genetic Variants in Inflammasome Regulatory Genes" explores the role of rare genetic variations in the regulation of the inflammasome, a crucial component of the innate immune system, and their potential involvement in the development of multiple sclerosis (MS). Using whole exome sequencing, the research team investigated 62 genes related to the NLRP1/NLRP3 inflammasome network in a cohort of 319 individuals, including familial and sporadic MS patients, as well as control subjects.

Background
Multiple sclerosis is a complex immune-mediated neurodegenerative disease characterized by the immune system attacking the myelin sheath, which insulates nerve fibers. While the disease is known to be influenced by both genetic and environmental factors—particularly Epstein-Barr virus (EBV) infection—research into the genetic contribution to MS has largely focused on common variants through genome-wide association studies (GWAS). However, rare genetic variants, especially those with minor allele frequencies (MAF) below 0.0001, have been difficult to study due to limitations in GWAS methodologies. This study seeks to fill that gap by investigating exceedingly rare variants that might contribute to MS.

Study Objectives
The primary objective of the study was to assess the mutational burden of rare genetic variants in inflammasome regulatory genes among MS patients compared to control subjects. The authors focused on genes involved in the NLRP1/NLRP3 inflammasome complex, which is pivotal for immune responses and inflammation. They hypothesized that rare variants in these genes could disrupt normal inflammasome function, leading to an increased risk of MS.

Methods
The researchers performed whole exome sequencing on DNA samples from 319 subjects. These subjects were divided into three groups: 86 familial MS probands, 89 sporadic MS patients, and 144 control subjects. They screened 62 genes involved in the regulation of the inflammasome, focusing on identifying rare protein-altering variants.

The study utilized two key metrics to assess the potential impact of these variants: MAF and CADD (Combined Annotation-Dependent Depletion) scores. CADD scores are used to predict the pathogenicity of variants, with higher scores indicating a higher likelihood of deleterious effects on protein function. Variants with CADD scores above 20 were considered highly pathogenic.

Results
The study identified 300 rare protein-altering variants across the 62 inflammasome-related genes. Both familial and sporadic MS patients exhibited a significantly higher burden of these rare variants compared to controls. The burden was most pronounced for exceedingly rare variants with high predicted pathogenicity. Some of the most affected genes included NLRP1, NLRP3, CASP1, and RIPK2—key regulators of the inflammasome and immune response.

A notable finding was the identification of several rare variants in the POLR3A gene, which encodes a subunit of RNA polymerase III. This enzyme plays a crucial role in detecting viral DNA and triggering immune responses, including the production of interferon-β, a key antiviral cytokine. Variants in POLR3A, along with other genes involved in the detection of viral DNA and RNA, such as IFIH1 and DHX58.

Discussion
The study provides new evidence supporting the role of rare genetic variants in the inflammasome pathway in the development of MS. The findings are significant because they highlight the contribution of exceedingly rare variants, which are not captured by traditional GWAS, to MS risk. These variants likely disrupt inflammasome function, leading to dysregulated immune responses and increased inflammation.

One of the key insights from this study is the potential link between viral infections, particularly EBV, and genetic susceptibility to MS. Several of the identified variants affect genes involved in antiviral responses, including interferon-β signaling, which is already a well-established therapeutic target in MS.

Conclusion
This study represents a significant step forward in understanding the genetic underpinnings of multiple sclerosis, particularly in the context of rare variants in the inflammasome regulatory network. By identifying an increased burden of highly pathogenic, exceedingly rare variants in MS patients, the research underscores the importance of rare genetic variation in disease risk. Moreover, the study provides a compelling argument for further investigation into the role of inflammasome dysregulation and viral infections in MS pathogenesis.

Reference:
Vidmar, L., Maver, A., Drulović, J. et al. Multiple Sclerosis patients carry an increased burden of exceedingly rare genetic variants in the inflammasome regulatory genes. Sci Rep 9, 9171 (2019).